Haleon plc
HealthcareNYSE:HLN · New York Stock Exchange
+$0.10 today
Vol 7.92M · Avg 8.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.9%
avg 6.2%
ROIC
6.6%
avg 4.5%
ROA
5.0%
avg 3.5%
Analysis
ROE is currently the strongest return metric at 9.9% versus its period average of 6.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian James McNamara | Chief Executive Officer & Executive Director | $3.82M | — | 60 | — | — |
Dawn Amanda Allen | Chief Financial Officer & Director | $2.06M | — | 58 | — | — |
Adrian Charles Morris | General Counsel | — | — | 59 | — | — |
Bjorn Timelin | Head of Strategy | — | — | — | — | — |
Filippo Lanzi | President of EMEA & LatAm | — | — | — | — | — |
Keith Choy | President of Asia Pacific | — | — | 57 | — | — |
Claire Dickson | Chief Digital & Technology Officer | — | — | — | — | — |
Joanne Russell | Head of Investor Relations | — | — | — | — | — |
Line De Decker | Chief Human Resources Officer | — | — | 52 | — | — |
Namrata Patel | Chief Supply Chain Officer | — | — | 60 | — | — |
Tamara Rogers | Chief Marketing Officer | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +0.0% | +13.1% (7yr)5 analysts |
| Revenue | N/A | N/A | +4.5% | +2.7% (7yr)7 analysts |
| Net Income | N/A | N/A | -2.9% | +13.5% (7yr)7 analysts |
| EBIT | N/A | N/A | +7.7% | +8.5% (7yr)7 analysts |
Analysis
Recent growth has been strongest in EBIT at +7.7% over three years. Forward estimates point to Net Income at +13.5% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.98B
Cardinal Health, Inc.
NYSE:CAH
$52.43B
Takeda Pharmaceutical Company Limited
NYSE:TAK
$50.27B
Humana Inc.
NYSE:HUM
$45.53B
Agilent Technologies, Inc.
NYSE:A
$36.67B
Zoetis Inc.
NYSE:ZTS
$33.36B
Alcon Inc.
NYSE:ALC
$32.58B
IQVIA Holdings Inc.
NYSE:IQV
$30.29B
ResMed Inc.
NYSE:RMD
$28.25B
Insmed Incorporated
NASDAQ:INSM
$21.21B
Who manages HLN?
Haleon plc (HLN) lists 11 active executives. The top listed executive is Adrian Charles Morris, General Counsel.
Explore More
Continue the stock analysis
Jump to another research area for this company.